Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-miR-21-5p | AKT2 | 1.51 | 0 | -0.34 | 1.0E-5 | miRNAWalker2 validate | -0.25 | 0 | NA | |
| 2 | hsa-miR-330-5p | AKT2 | 0.44 | 0.00533 | -0.34 | 1.0E-5 | miRanda | -0.1 | 1.0E-5 | NA | |
| 3 | hsa-miR-342-3p | AKT2 | -0.32 | 0.04498 | -0.34 | 1.0E-5 | mirMAP | -0.12 | 0 | NA | |
| 4 | hsa-miR-106b-5p | AKT3 | 0.65 | 0 | -0.66 | 0.00047 | miRNATAP | -0.26 | 0.00148 | NA | |
| 5 | hsa-miR-107 | AKT3 | 0.24 | 0.01708 | -0.66 | 0.00047 | PITA; miRanda | -0.6 | 0 | NA | |
| 6 | hsa-miR-122-5p | AKT3 | -1.24 | 0 | -0.66 | 0.00047 | miRNAWalker2 validate; miRTarBase | -0.28 | 0 | 24244539 | miR 122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3; Here we identify AKT3 as a novel and direct target of miR-122; Restoration of miR-122 expression in HCC cell lines decreases AKT3 levels inhibits cell migration and proliferation and induces apoptosis; These anti-tumor phenotypes can be rescued by reconstitution of AKT3 expression indicating the essential role of AKT3 in miR-122 mediated HCC transformation; Our data strongly suggest that miR-122 is a tumor suppressor that targets AKT3 to regulate tumorigenesis in HCCs and a potential therapeutic candidate for liver cancer |
| 7 | hsa-miR-146b-5p | AKT3 | 0.42 | 0.04574 | -0.66 | 0.00047 | miRNAWalker2 validate | -0.16 | 0.00026 | NA | |
| 8 | hsa-miR-15a-5p | AKT3 | 0.35 | 0.00077 | -0.66 | 0.00047 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.27 | 0.00291 | NA | |
| 9 | hsa-miR-17-3p | AKT3 | 0.41 | 0.00422 | -0.66 | 0.00047 | miRNATAP | -0.35 | 0 | NA | |
| 10 | hsa-miR-17-5p | AKT3 | 0.7 | 2.0E-5 | -0.66 | 0.00047 | TargetScan; miRNATAP | -0.29 | 0 | NA | |
| 11 | hsa-miR-20a-5p | AKT3 | 0.85 | 0 | -0.66 | 0.00047 | miRNATAP | -0.29 | 0 | NA | |
| 12 | hsa-miR-32-3p | AKT3 | 0.22 | 0.20722 | -0.66 | 0.00047 | mirMAP | -0.23 | 4.0E-5 | NA | |
| 13 | hsa-miR-33a-3p | AKT3 | -0.68 | 1.0E-5 | -0.66 | 0.00047 | mirMAP | -0.23 | 0.0001 | NA | |
| 14 | hsa-miR-362-3p | AKT3 | 0.81 | 0 | -0.66 | 0.00047 | miRanda | -0.22 | 0.00083 | NA | |
| 15 | hsa-miR-362-5p | AKT3 | 0.72 | 2.0E-5 | -0.66 | 0.00047 | PITA; TargetScan; miRNATAP | -0.15 | 0.00734 | NA | |
| 16 | hsa-miR-374a-5p | AKT3 | 0.02 | 0.86978 | -0.66 | 0.00047 | mirMAP | -0.28 | 0.00294 | NA | |
| 17 | hsa-miR-502-3p | AKT3 | 0.66 | 0 | -0.66 | 0.00047 | miRNATAP | -0.26 | 0.0008 | NA | |
| 18 | hsa-miR-616-5p | AKT3 | 0.15 | 0.40284 | -0.66 | 0.00047 | mirMAP | -0.2 | 0.0001 | NA | |
| 19 | hsa-miR-93-5p | AKT3 | 1.4 | 0 | -0.66 | 0.00047 | miRNATAP | -0.28 | 1.0E-5 | NA | |
| 20 | hsa-let-7a-5p | HRAS | -0.33 | 0.00046 | 0.81 | 0 | miRNAWalker2 validate; miRTarBase | -0.41 | 0 | 20607356; 23134218; 18344688; 20033209; 19323605 | Transfection of let-7 miRNA reduced expression of pan-RAS N-RAS and K-RAS in the glioblastoma cells;MicroRNA let 7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K Ras and HMGA2 gene expression; K-RAS and HMGA2 mRNA levels were significantly higher in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; However the protein levels of K-RAS and HMGA2 were significantly lower in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; We suppose that let-7a inhibits the proliferation and invasion of the cell line 95D by regulating the translation of K-RAS and HMGA2 mRNA not the transcription of the mRNA itself;Using an established orthotopic mouse lung cancer model we show that intranasal let-7 administration reduces tumor formation in vivo in the lungs of animals expressing a G12D activating mutation for the K-ras oncogene;k-Ras and c-Myc two key oncogenes in lung cancer have been found to be targeted by let-7 in vitro; The aim of the present study is to determine the effect of let-7a a member of let-7 family on the growth of lung cancer in vivo and to investigate whether let-7-induced suppression of k-Ras and c-Myc is involved in lung cancer; Overexpression of let-7a can inhibit the growth of lung cancer transplanted subcutaneously in nude mice by suppression of k-Ras and c-Myc;Because let-7 microRNA targets the K-ras oncogene we aimed to characterize let-7 expression and function in PDAC in vitro and in vivo; Restoring let-7 levels in cancer-derived cell lines strongly inhibits cell proliferation K-ras expression and mitogen-activated protein kinase activation but fails to impede tumor growth progression after intratumoral gene transfer or after implantation of Capan-1 cells stably overexpressing let-7 microRNA |
| 21 | hsa-let-7b-5p | HRAS | -0.96 | 0 | 0.81 | 0 | miRTarBase | -0.27 | 0 | 20607356; 20881268; 18344688; 20033209; 19323605 | Transfection of let-7 miRNA reduced expression of pan-RAS N-RAS and K-RAS in the glioblastoma cells;On the basis of these data we suggest that the downregulation of let-7b and let-7e targeting K-ras and the upregulation of miR-17* a CRC marker could be considered as candidate molecular markers of cetuximab resistance;Using an established orthotopic mouse lung cancer model we show that intranasal let-7 administration reduces tumor formation in vivo in the lungs of animals expressing a G12D activating mutation for the K-ras oncogene;k-Ras and c-Myc two key oncogenes in lung cancer have been found to be targeted by let-7 in vitro; The aim of the present study is to determine the effect of let-7a a member of let-7 family on the growth of lung cancer in vivo and to investigate whether let-7-induced suppression of k-Ras and c-Myc is involved in lung cancer;Because let-7 microRNA targets the K-ras oncogene we aimed to characterize let-7 expression and function in PDAC in vitro and in vivo; Restoring let-7 levels in cancer-derived cell lines strongly inhibits cell proliferation K-ras expression and mitogen-activated protein kinase activation but fails to impede tumor growth progression after intratumoral gene transfer or after implantation of Capan-1 cells stably overexpressing let-7 microRNA |
| 22 | hsa-miR-143-3p | HRAS | -0.58 | 0.00091 | 0.81 | 0 | miRNAWalker2 validate; miRTarBase | -0.14 | 7.0E-5 | 21276449 | The Evi1 microRNA 143 K Ras axis in colon cancer |
| 23 | hsa-miR-542-3p | JMJD7-PLA2G4B | -1.31 | 0 | 0.29 | 0.00124 | miRNATAP | -0.12 | 8.0E-5 | NA | |
| 24 | hsa-miR-149-5p | KDR | -0.32 | 0.18721 | -0.81 | 1.0E-5 | miRNATAP | -0.16 | 1.0E-5 | NA | |
| 25 | hsa-miR-15a-5p | KDR | 0.35 | 0.00077 | -0.81 | 1.0E-5 | miRNATAP | -0.37 | 1.0E-5 | NA | |
| 26 | hsa-miR-15b-5p | KDR | 0.23 | 0.08248 | -0.81 | 1.0E-5 | miRNATAP | -0.34 | 0 | NA | |
| 27 | hsa-miR-200c-3p | KDR | -0.1 | 0.71696 | -0.81 | 1.0E-5 | miRNATAP | -0.12 | 0.00017 | 24205206 | MiR 200c increases the radiosensitivity of non small cell lung cancer cell line A549 by targeting VEGF VEGFR2 pathway; MiR-200c at the nexus of epithelial-mesenchymal transition EMT is predicted to target VEGFR2; The purpose of this study is to test the hypothesis that regulation of VEGFR2 pathway by miR-200c could modulate the radiosensitivity of cancer cells; Bioinformatic analysis luciferase reporter assays and biochemical assays were carried out to validate VEGFR2 as a direct target of miR-200c; We identified VEGFR2 as a novel target of miR-200c |
| 28 | hsa-miR-338-3p | KDR | 0.54 | 0.00461 | -0.81 | 1.0E-5 | PITA; miRanda | -0.12 | 0.00756 | NA | |
| 29 | hsa-miR-590-5p | KDR | -0.1 | 0.31003 | -0.81 | 1.0E-5 | miRanda | -0.64 | 0 | NA | |
| 30 | hsa-miR-618 | KDR | 0.14 | 0.51715 | -0.81 | 1.0E-5 | PITA | -0.14 | 0.00225 | NA | |
| 31 | hsa-miR-140-3p | KRAS | 0.55 | 0 | -0.34 | 0.00044 | MirTarget | -0.25 | 1.0E-5 | NA | |
| 32 | hsa-miR-16-1-3p | KRAS | 0.39 | 0.00112 | -0.34 | 0.00044 | mirMAP | -0.11 | 0.0033 | NA | |
| 33 | hsa-miR-193a-3p | KRAS | -0.12 | 0.30939 | -0.34 | 0.00044 | MirTarget; miRanda; miRNATAP | -0.13 | 0.00171 | NA | |
| 34 | hsa-miR-193b-3p | KRAS | -0.17 | 0.27202 | -0.34 | 0.00044 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.12 | 0.0001 | 25905463 | Deregulation of the MiR 193b KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer; Mechanistically KRAS was verified as a direct effector of miR-193b through which the AKT and ERK pathways were modulated and cell growth of PDAC cells was suppressed; Taken together our findings indicate that miR-193b-mediated deregulation of the KRAS axis is involved in pancreatic carcinogenesis and suggest that miR-193b could be a potentially effective target for PDAC therapy |
| 35 | hsa-miR-30d-3p | KRAS | -0.12 | 0.32955 | -0.34 | 0.00044 | MirTarget; miRNATAP | -0.13 | 0.00051 | NA | |
| 36 | hsa-miR-532-5p | KRAS | 1.03 | 0 | -0.34 | 0.00044 | MirTarget; PITA; miRNATAP | -0.14 | 0.0001 | NA | |
| 37 | hsa-miR-140-3p | MAP2K1 | 0.55 | 0 | -1.23 | 0 | PITA | -0.38 | 0 | NA | |
| 38 | hsa-miR-34a-5p | MAP2K1 | 1.04 | 0 | -1.23 | 0 | miRNAWalker2 validate; miRTarBase | -0.23 | 0 | NA | |
| 39 | hsa-miR-361-5p | MAP2K1 | 0.23 | 0.00962 | -1.23 | 0 | miRanda | -0.18 | 0.00107 | NA | |
| 40 | hsa-miR-501-5p | MAP2K1 | 1.15 | 0 | -1.23 | 0 | PITA | -0.14 | 0 | NA | |
| 41 | hsa-let-7b-5p | MAP2K2 | -0.96 | 0 | 0.63 | 0 | miRNAWalker2 validate | -0.18 | 0 | NA | |
| 42 | hsa-miR-122-5p | MAPK11 | -1.24 | 0 | 1.21 | 0 | miRNAWalker2 validate; miRTarBase | -0.1 | 0.00151 | NA | |
| 43 | hsa-miR-27a-3p | MAPK14 | -0.37 | 0.00876 | -0.14 | 0.04955 | MirTarget; miRNATAP | -0.14 | 0 | NA | |
| 44 | hsa-miR-27b-5p | MAPKAPK2 | -0.08 | 0.48087 | 0.54 | 0 | mirMAP | -0.19 | 0 | NA | |
| 45 | hsa-miR-320a | MAPKAPK2 | 0.33 | 0.02214 | 0.54 | 0 | miRanda | -0.11 | 0.00098 | NA | |
| 46 | hsa-miR-486-5p | MAPKAPK2 | -1.78 | 0 | 0.54 | 0 | miRanda | -0.1 | 0 | NA | |
| 47 | hsa-miR-148b-3p | NFAT5 | 0.27 | 0.00185 | -0.33 | 0.00164 | miRNATAP | -0.21 | 0.00043 | NA | |
| 48 | hsa-miR-17-3p | NFAT5 | 0.41 | 0.00422 | -0.33 | 0.00164 | mirMAP | -0.1 | 0.003 | NA | |
| 49 | hsa-miR-192-3p | NFAT5 | -0.64 | 0.00027 | -0.33 | 0.00164 | MirTarget; miRNATAP | -0.13 | 1.0E-5 | NA | |
| 50 | hsa-miR-193a-3p | NFAT5 | -0.12 | 0.30939 | -0.33 | 0.00164 | miRanda | -0.16 | 0.00017 | NA | |
| 51 | hsa-miR-194-3p | NFAT5 | -0.77 | 3.0E-5 | -0.33 | 0.00164 | miRNATAP | -0.11 | 3.0E-5 | NA | |
| 52 | hsa-miR-194-5p | NFAT5 | -0.29 | 0.09961 | -0.33 | 0.00164 | miRNATAP | -0.12 | 2.0E-5 | NA | |
| 53 | hsa-miR-21-5p | NFAT5 | 1.51 | 0 | -0.33 | 0.00164 | miRNAWalker2 validate; mirMAP | -0.11 | 0.00342 | NA | |
| 54 | hsa-miR-30d-5p | NFAT5 | 0.72 | 0 | -0.33 | 0.00164 | MirTarget; miRNATAP | -0.1 | 0.00926 | NA | |
| 55 | hsa-miR-362-5p | NFAT5 | 0.72 | 2.0E-5 | -0.33 | 0.00164 | mirMAP | -0.1 | 0.00051 | NA | |
| 56 | hsa-miR-548j-5p | NFAT5 | 0.25 | 0.17136 | -0.33 | 0.00164 | MirTarget | -0.11 | 5.0E-5 | NA | |
| 57 | hsa-miR-885-5p | NFAT5 | -0.94 | 0.00119 | -0.33 | 0.00164 | PITA | -0.14 | 0 | NA | |
| 58 | hsa-miR-455-5p | NFATC1 | -0.27 | 0.05813 | -0.75 | 4.0E-5 | miRanda | -0.31 | 0 | NA | |
| 59 | hsa-miR-29a-5p | NFATC2 | -0.11 | 0.34962 | -1.87 | 0 | mirMAP; miRNATAP | -0.58 | 6.0E-5 | NA | |
| 60 | hsa-miR-30d-5p | NFATC2 | 0.72 | 0 | -1.87 | 0 | MirTarget; mirMAP | -0.43 | 0.00143 | NA | |
| 61 | hsa-miR-15a-5p | NFATC3 | 0.35 | 0.00077 | -0.64 | 0 | MirTarget; miRNATAP | -0.14 | 0.00111 | NA | |
| 62 | hsa-miR-185-5p | NFATC3 | 0.48 | 0 | -0.64 | 0 | MirTarget; miRNATAP | -0.18 | 0.0001 | NA | |
| 63 | hsa-miR-222-3p | NFATC3 | 1.09 | 0 | -0.64 | 0 | MirTarget; miRNATAP | -0.13 | 0 | NA | |
| 64 | hsa-miR-30d-5p | NFATC3 | 0.72 | 0 | -0.64 | 0 | MirTarget; miRNATAP | -0.11 | 0.00162 | NA | |
| 65 | hsa-miR-324-3p | NFATC3 | 0.26 | 0.05061 | -0.64 | 0 | miRNAWalker2 validate | -0.11 | 0.00063 | NA | |
| 66 | hsa-miR-335-3p | NFATC3 | -0.28 | 0.10663 | -0.64 | 0 | mirMAP | -0.13 | 0 | NA | |
| 67 | hsa-miR-339-5p | NFATC3 | 0.28 | 0.03557 | -0.64 | 0 | miRanda | -0.17 | 0 | NA | |
| 68 | hsa-miR-362-3p | NFATC3 | 0.81 | 0 | -0.64 | 0 | miRanda | -0.17 | 0 | NA | |
| 69 | hsa-miR-589-3p | NFATC3 | 1.17 | 0 | -0.64 | 0 | mirMAP | -0.15 | 0 | NA | |
| 70 | hsa-miR-125b-5p | NFATC4 | -1.36 | 0 | 0.86 | 2.0E-5 | mirMAP | -0.22 | 0.00027 | NA | |
| 71 | hsa-miR-130b-5p | NFATC4 | 0.17 | 0.33761 | 0.86 | 2.0E-5 | mirMAP | -0.22 | 6.0E-5 | NA | |
| 72 | hsa-miR-29a-3p | NFATC4 | -0.86 | 0 | 0.86 | 2.0E-5 | miRNATAP | -0.21 | 0.00743 | NA | |
| 73 | hsa-miR-3607-3p | NFATC4 | -2.16 | 0 | 0.86 | 2.0E-5 | miRNATAP | -0.17 | 6.0E-5 | NA | |
| 74 | hsa-let-7b-5p | NRAS | -0.96 | 0 | 0.3 | 0.00029 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.11 | 9.0E-5 | 20607356 | Transfection of let-7 miRNA reduced expression of pan-RAS N-RAS and K-RAS in the glioblastoma cells |
| 75 | hsa-miR-126-5p | NRAS | -0.43 | 7.0E-5 | 0.3 | 0.00029 | mirMAP | -0.15 | 0.00011 | NA | |
| 76 | hsa-miR-145-5p | NRAS | -1.48 | 0 | 0.3 | 0.00029 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.12 | 0 | 26973415 | miR-145 expression was significantly downregulated in colon cancer tissues with its expression in normal colonic tissues being 4-5-fold higher two sample t test P < 0.05 whereas N-ras expression showed the opposite trend |
| 77 | hsa-miR-22-3p | NRAS | -0.63 | 0 | 0.3 | 0.00029 | MirTarget; miRNATAP | -0.29 | 0 | NA | |
| 78 | hsa-miR-29a-3p | NRAS | -0.86 | 0 | 0.3 | 0.00029 | miRNATAP | -0.11 | 0.0005 | NA | |
| 79 | hsa-miR-29b-3p | NRAS | -0.35 | 0.01214 | 0.3 | 0.00029 | miRNATAP | -0.16 | 0 | NA | |
| 80 | hsa-miR-29c-3p | NRAS | -1.44 | 0 | 0.3 | 0.00029 | miRNATAP | -0.2 | 0 | NA | |
| 81 | hsa-miR-664a-3p | NRAS | 0.49 | 0.00073 | 0.3 | 0.00029 | MirTarget | -0.12 | 1.0E-5 | NA | |
| 82 | hsa-miR-17-5p | PIK3CA | 0.7 | 2.0E-5 | -0.42 | 0.00014 | miRNAWalker2 validate | -0.14 | 1.0E-5 | NA | |
| 83 | hsa-miR-339-5p | PIK3CA | 0.28 | 0.03557 | -0.42 | 0.00014 | miRanda | -0.16 | 6.0E-5 | NA | |
| 84 | hsa-miR-501-5p | PIK3CA | 1.15 | 0 | -0.42 | 0.00014 | mirMAP | -0.11 | 0.00012 | NA | |
| 85 | hsa-miR-126-5p | PIK3CB | -0.43 | 7.0E-5 | 0.1 | 0.16595 | mirMAP | -0.18 | 0 | NA | |
| 86 | hsa-miR-204-5p | PIK3CB | -0.54 | 0.03309 | 0.1 | 0.16595 | miRNATAP | -0.11 | 0 | NA | |
| 87 | hsa-miR-32-5p | PIK3CB | 0.08 | 0.54898 | 0.1 | 0.16595 | miRNATAP | -0.14 | 0 | NA | |
| 88 | hsa-miR-1468-5p | PIK3CD | -1.21 | 0 | -0.88 | 0 | MirTarget | -0.11 | 0.00956 | NA | |
| 89 | hsa-miR-30b-3p | PIK3CD | -0.44 | 0.00095 | -0.88 | 0 | MirTarget | -0.24 | 0.00045 | NA | |
| 90 | hsa-miR-30d-5p | PIK3CD | 0.72 | 0 | -0.88 | 0 | MirTarget; miRNATAP | -0.31 | 1.0E-5 | NA | |
| 91 | hsa-miR-30e-5p | PIK3CD | -0.63 | 0 | -0.88 | 0 | MirTarget | -0.25 | 0.00529 | NA | |
| 92 | hsa-miR-616-5p | PIK3CD | 0.15 | 0.40284 | -0.88 | 0 | MirTarget | -0.21 | 5.0E-5 | NA | |
| 93 | hsa-miR-103a-3p | PIK3R1 | 0.77 | 0 | -0.89 | 0 | MirTarget; miRNATAP | -0.19 | 0.00703 | NA | |
| 94 | hsa-miR-106b-5p | PIK3R1 | 0.65 | 0 | -0.89 | 0 | MirTarget; miRNATAP | -0.37 | 0 | NA | |
| 95 | hsa-miR-1301-3p | PIK3R1 | 1.12 | 0 | -0.89 | 0 | MirTarget | -0.26 | 0 | NA | |
| 96 | hsa-miR-132-3p | PIK3R1 | 0.32 | 0.00272 | -0.89 | 0 | MirTarget | -0.52 | 0 | NA | |
| 97 | hsa-miR-17-5p | PIK3R1 | 0.7 | 2.0E-5 | -0.89 | 0 | MirTarget; TargetScan; miRNATAP | -0.21 | 0 | NA | |
| 98 | hsa-miR-185-5p | PIK3R1 | 0.48 | 0 | -0.89 | 0 | miRNATAP | -0.26 | 0.00154 | NA | |
| 99 | hsa-miR-188-5p | PIK3R1 | 1.12 | 0 | -0.89 | 0 | MirTarget | -0.18 | 5.0E-5 | NA | |
| 100 | hsa-miR-200c-3p | PIK3R1 | -0.1 | 0.71696 | -0.89 | 0 | mirMAP | -0.11 | 9.0E-5 | NA | |
| 101 | hsa-miR-20a-5p | PIK3R1 | 0.85 | 0 | -0.89 | 0 | MirTarget; miRNATAP | -0.14 | 0.00238 | NA | |
| 102 | hsa-miR-21-5p | PIK3R1 | 1.51 | 0 | -0.89 | 0 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.63 | 0 | 26676464 | PIK3R1 targeting by miR 21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT and predicts clinical outcome of breast cancer; Next we identified the PIK3R1 as a direct target of miR-21 and showed that it was negatively regulated by miR-21; Taken together we provide novel evidence that miR-21 knockdown suppresses cell growth migration and invasion partly by inhibiting PI3K/AKT activation via direct targeting PIK3R1 and reversing EMT in breast cancer |
| 103 | hsa-miR-212-3p | PIK3R1 | -0.29 | 0.10039 | -0.89 | 0 | MirTarget | -0.26 | 0 | NA | |
| 104 | hsa-miR-221-3p | PIK3R1 | 1.12 | 0 | -0.89 | 0 | MirTarget | -0.22 | 1.0E-5 | NA | |
| 105 | hsa-miR-222-3p | PIK3R1 | 1.09 | 0 | -0.89 | 0 | MirTarget | -0.26 | 0 | NA | |
| 106 | hsa-miR-324-3p | PIK3R1 | 0.26 | 0.05061 | -0.89 | 0 | MirTarget; PITA; miRNATAP | -0.28 | 0 | NA | |
| 107 | hsa-miR-330-3p | PIK3R1 | -0.33 | 0.03161 | -0.89 | 0 | MirTarget; PITA; miRNATAP | -0.21 | 3.0E-5 | NA | |
| 108 | hsa-miR-338-5p | PIK3R1 | -0.22 | 0.25239 | -0.89 | 0 | PITA | -0.14 | 0.00037 | NA | |
| 109 | hsa-miR-409-3p | PIK3R1 | -0.5 | 0.05268 | -0.89 | 0 | mirMAP | -0.11 | 0.00024 | NA | |
| 110 | hsa-miR-493-5p | PIK3R1 | -0.2 | 0.50287 | -0.89 | 0 | MirTarget; miRNATAP | -0.1 | 8.0E-5 | NA | |
| 111 | hsa-miR-582-5p | PIK3R1 | -0.68 | 0.00104 | -0.89 | 0 | mirMAP | -0.14 | 0.00021 | NA | |
| 112 | hsa-miR-589-3p | PIK3R1 | 1.17 | 0 | -0.89 | 0 | mirMAP | -0.21 | 0 | NA | |
| 113 | hsa-miR-590-5p | PIK3R1 | -0.1 | 0.31003 | -0.89 | 0 | MirTarget; PITA; miRanda; miRNATAP | -0.3 | 0.0001 | NA | |
| 114 | hsa-miR-629-3p | PIK3R1 | -0.32 | 0.11909 | -0.89 | 0 | MirTarget | -0.18 | 0 | NA | |
| 115 | hsa-miR-93-5p | PIK3R1 | 1.4 | 0 | -0.89 | 0 | MirTarget; miRNATAP | -0.32 | 0 | NA | |
| 116 | hsa-miR-126-3p | PIK3R2 | -0.65 | 0 | 0.9 | 0 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | 25240815; 26384552; 27578985; 21249429; 26191164 | MiR 126 3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2; LRP6 and PIK3R2 were identified as targets of miR-126-3p; Silencing LRP6 and PIK3R2 had similar effects of miR-126-3p restoration on metastasis and angiogenesis individually in HCC cells; Furthermore the miR-126-3p level was inversely correlated with LRP6 and PIK3R2 in HCC tissues; In addition the rescue experiments indicated that the metastasis and angiogenesis functions of miR-126-3p were mediated by LRP6 and PIK3R2;MicroRNA 126 suppresses proliferation of undifferentiated BRAFV600E and BRAFWT thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K AKT proliferation survival signalling pathway; In addition miR-126 was found to act as proliferation suppressor targeting PIK3R2 gene and reducing p85β a regulatory subunit of PI3K kinase protein translation and lower AKT kinase activity;MiR 126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2 mediated PI3K/Akt signaling pathway; A direct regulatory relationship between miR-126 and the PIK3R2 gene was demonstrated by luciferase reporter assays; Quantitative real-time polymerase chain reaction was used to measure miR-126 and PIK3R2 expressions; Luciferase assays showed that miR-126 significantly inhibited the PIK3R2 3' untranslated region 3'UTR luciferase reporter activity P<0.05; Overexpression of miR-126 negatively regulated the target gene PIK3R2 and further inhibited the PI3K/Akt signaling pathway thereby inhibiting proliferation migration and invasion and promoting apoptosis in BLS cells;Endothelial specific intron derived miR 126 is down regulated in human breast cancer and targets both VEGFA and PIK3R2; VEGFA and PIK3R2 were confirmed as the targets of miR-126 by luciferase reporter assay and Western blot;Restoration of miR-126 in EC109 cells induced a reduction in PIK3R2 protein levels accompanied with a substantial reduction in phosphorylated AKT levels in EC109 cells suggesting impairment in PI3K/AKT signaling pathway; The luciferase reporter assay confirmed that PIK3R2 was a direct target of miR-126; Taken together our study suggests that miR-126 functions as a potential tumor suppressor in ESCC progression via regulating PI3K/AKT signaling pathway partly by targeting PIK3R2 and targeting of miR-126 may provide a novel strategy for the diagnosis and treatment of ESCC |
| 117 | hsa-miR-28-5p | PIK3R2 | -0.43 | 0 | 0.9 | 0 | miRanda | -0.22 | 0.00079 | NA | |
| 118 | hsa-miR-30a-5p | PIK3R2 | -0.63 | 0.00011 | 0.9 | 0 | miRNATAP | -0.14 | 7.0E-5 | NA | |
| 119 | hsa-miR-30e-5p | PIK3R2 | -0.63 | 0 | 0.9 | 0 | miRNATAP | -0.27 | 0 | NA | |
| 120 | hsa-miR-3607-3p | PIK3R2 | -2.16 | 0 | 0.9 | 0 | mirMAP; miRNATAP | -0.19 | 0 | NA | |
| 121 | hsa-miR-19a-3p | PIK3R3 | 1.02 | 0 | 0.64 | 0 | MirTarget; miRNATAP | -0.1 | 0.00019 | NA | |
| 122 | hsa-miR-19b-3p | PIK3R3 | 0.6 | 0.00017 | 0.64 | 0 | MirTarget; miRNATAP | -0.16 | 1.0E-5 | NA | |
| 123 | hsa-miR-222-5p | PIK3R3 | 0.13 | 0.48742 | 0.64 | 0 | mirMAP | -0.12 | 7.0E-5 | NA | |
| 124 | hsa-miR-32-5p | PIK3R3 | 0.08 | 0.54898 | 0.64 | 0 | MirTarget; miRNATAP | -0.12 | 0.00655 | NA | |
| 125 | hsa-miR-331-3p | PIK3R3 | -0.28 | 0.03738 | 0.64 | 0 | miRNAWalker2 validate; PITA | -0.14 | 0.00066 | NA | |
| 126 | hsa-miR-335-3p | PIK3R3 | -0.28 | 0.10663 | 0.64 | 0 | mirMAP | -0.16 | 0 | NA | |
| 127 | hsa-miR-454-3p | PIK3R3 | 0.67 | 0 | 0.64 | 0 | mirMAP | -0.16 | 8.0E-5 | NA | |
| 128 | hsa-miR-590-5p | PIK3R3 | -0.1 | 0.31003 | 0.64 | 0 | miRanda | -0.24 | 1.0E-5 | NA | |
| 129 | hsa-miR-624-5p | PIK3R3 | -0.64 | 1.0E-5 | 0.64 | 0 | MirTarget | -0.12 | 0.00156 | NA | |
| 130 | hsa-miR-92a-3p | PIK3R3 | 0.21 | 0.13429 | 0.64 | 0 | MirTarget; miRNATAP | -0.21 | 0 | NA | |
| 131 | hsa-miR-107 | PIK3R5 | 0.24 | 0.01708 | -0.9 | 0 | miRanda | -0.35 | 3.0E-5 | NA | |
| 132 | hsa-miR-106b-5p | PLA2G12A | 0.65 | 0 | -0.79 | 0 | mirMAP | -0.27 | 0 | NA | |
| 133 | hsa-miR-140-5p | PLA2G12A | -0.22 | 0.01407 | -0.79 | 0 | miRanda | -0.15 | 0.00839 | NA | |
| 134 | hsa-miR-17-5p | PLA2G12A | 0.7 | 2.0E-5 | -0.79 | 0 | mirMAP | -0.16 | 0 | NA | |
| 135 | hsa-miR-181a-5p | PLA2G12A | 0.25 | 0.05519 | -0.79 | 0 | mirMAP | -0.19 | 0 | NA | |
| 136 | hsa-miR-181b-5p | PLA2G12A | 0.49 | 0.00105 | -0.79 | 0 | mirMAP | -0.19 | 0 | NA | |
| 137 | hsa-miR-20a-5p | PLA2G12A | 0.85 | 0 | -0.79 | 0 | mirMAP | -0.13 | 1.0E-5 | NA | |
| 138 | hsa-miR-32-3p | PLA2G12A | 0.22 | 0.20722 | -0.79 | 0 | mirMAP | -0.1 | 0.00072 | NA | |
| 139 | hsa-miR-362-3p | PLA2G12A | 0.81 | 0 | -0.79 | 0 | miRanda | -0.14 | 0.00017 | NA | |
| 140 | hsa-miR-501-5p | PLA2G12A | 1.15 | 0 | -0.79 | 0 | miRNATAP | -0.16 | 0 | NA | |
| 141 | hsa-miR-589-3p | PLA2G12A | 1.17 | 0 | -0.79 | 0 | mirMAP | -0.19 | 0 | NA | |
| 142 | hsa-miR-625-3p | PLA2G12A | 0.24 | 0.18123 | -0.79 | 0 | mirMAP | -0.14 | 0 | NA | |
| 143 | hsa-miR-92b-3p | PLA2G12A | 0.22 | 0.29619 | -0.79 | 0 | miRNAWalker2 validate | -0.1 | 2.0E-5 | NA | |
| 144 | hsa-miR-93-5p | PLA2G12A | 1.4 | 0 | -0.79 | 0 | mirMAP | -0.32 | 0 | NA | |
| 145 | hsa-miR-1976 | PLA2G12B | -0.43 | 0.00325 | -0.71 | 0.01591 | MirTarget | -0.45 | 0 | NA | |
| 146 | hsa-miR-28-5p | PLA2G1B | -0.43 | 0 | 1.11 | 0.001 | miRanda | -0.52 | 0.00381 | NA | |
| 147 | hsa-miR-361-5p | PLA2G2A | 0.23 | 0.00962 | -2.63 | 0.00019 | miRanda | -2.32 | 0 | NA | |
| 148 | hsa-miR-30c-2-3p | PLA2G2D | -1.4 | 0 | -0.89 | 0.03309 | mirMAP | -0.31 | 0.00508 | NA | |
| 149 | hsa-miR-361-5p | PLA2G4A | 0.23 | 0.00962 | -1.52 | 0 | miRanda | -0.52 | 0.00029 | NA | |
| 150 | hsa-miR-362-3p | PLA2G4A | 0.81 | 0 | -1.52 | 0 | miRanda | -0.27 | 0.00355 | NA |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 38 | 1929 | 1.036e-30 | 4.82e-27 |
| 2 | INTRACELLULAR SIGNAL TRANSDUCTION | 32 | 1572 | 7.872e-25 | 1.831e-21 |
| 3 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 34 | 1977 | 2.019e-24 | 3.132e-21 |
| 4 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 14 | 74 | 7.59e-24 | 8.83e-21 |
| 5 | FC RECEPTOR SIGNALING PATHWAY | 17 | 206 | 1.768e-22 | 1.645e-19 |
| 6 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 19 | 323 | 2.46e-22 | 1.908e-19 |
| 7 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 30 | 1656 | 1.853e-21 | 1.232e-18 |
| 8 | POSITIVE REGULATION OF CELL COMMUNICATION | 29 | 1532 | 4.029e-21 | 2.343e-18 |
| 9 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 20 | 498 | 3.017e-20 | 1.56e-17 |
| 10 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 14 | 142 | 1.201e-19 | 5.589e-17 |
| 11 | REGULATION OF IMMUNE SYSTEM PROCESS | 27 | 1403 | 1.361e-19 | 5.756e-17 |
| 12 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 23 | 876 | 2.541e-19 | 9.853e-17 |
| 13 | REGULATION OF IMMUNE RESPONSE | 22 | 858 | 3.381e-18 | 1.21e-15 |
| 14 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 22 | 867 | 4.218e-18 | 1.402e-15 |
| 15 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 27 | 1618 | 5.288e-18 | 1.64e-15 |
| 16 | REGULATION OF KINASE ACTIVITY | 21 | 776 | 8.62e-18 | 2.359e-15 |
| 17 | POSITIVE REGULATION OF MAPK CASCADE | 18 | 470 | 8.441e-18 | 2.359e-15 |
| 18 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 23 | 1036 | 1.039e-17 | 2.545e-15 |
| 19 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 23 | 1036 | 1.039e-17 | 2.545e-15 |
| 20 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 20 | 689 | 1.725e-17 | 4.012e-15 |
| 21 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 14 | 211 | 3.445e-17 | 7.633e-15 |
| 22 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 23 | 1135 | 7.686e-17 | 1.626e-14 |
| 23 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 14 | 235 | 1.57e-16 | 3.176e-14 |
| 24 | POSITIVE REGULATION OF KINASE ACTIVITY | 17 | 482 | 3.325e-16 | 6.446e-14 |
| 25 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 13 | 193 | 4.419e-16 | 8.225e-14 |
| 26 | REGULATION OF TRANSFERASE ACTIVITY | 21 | 946 | 4.658e-16 | 8.336e-14 |
| 27 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 13 | 207 | 1.105e-15 | 1.904e-13 |
| 28 | ACTIVATION OF IMMUNE RESPONSE | 16 | 427 | 1.157e-15 | 1.923e-13 |
| 29 | PHOSPHOLIPID METABOLIC PROCESS | 15 | 364 | 2.649e-15 | 4.25e-13 |
| 30 | REGULATION OF MAPK CASCADE | 18 | 660 | 3.204e-15 | 4.97e-13 |
| 31 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 14 | 297 | 4.111e-15 | 6.171e-13 |
| 32 | POSITIVE REGULATION OF IMMUNE RESPONSE | 17 | 563 | 4.321e-15 | 6.284e-13 |
| 33 | PHOSPHORYLATION | 22 | 1228 | 6.147e-15 | 8.667e-13 |
| 34 | REGULATION OF MAP KINASE ACTIVITY | 14 | 319 | 1.104e-14 | 1.511e-12 |
| 35 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 17 | 616 | 1.886e-14 | 2.508e-12 |
| 36 | LEUKOCYTE MIGRATION | 13 | 259 | 2.027e-14 | 2.619e-12 |
| 37 | POSITIVE REGULATION OF LOCOMOTION | 15 | 420 | 2.164e-14 | 2.721e-12 |
| 38 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 23 | 1492 | 2.825e-14 | 3.46e-12 |
| 39 | REGULATION OF PROTEIN MODIFICATION PROCESS | 24 | 1710 | 4.647e-14 | 5.544e-12 |
| 40 | GLYCEROLIPID METABOLIC PROCESS | 14 | 356 | 4.993e-14 | 5.808e-12 |
| 41 | PHOSPHATIDYLETHANOLAMINE ACYL CHAIN REMODELING | 7 | 23 | 5.909e-14 | 6.706e-12 |
| 42 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 13 | 289 | 8.294e-14 | 9.188e-12 |
| 43 | PROTEIN PHOSPHORYLATION | 19 | 944 | 1.063e-13 | 1.15e-11 |
| 44 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 24 | 1805 | 1.531e-13 | 1.619e-11 |
| 45 | PHOSPHATIDYLCHOLINE ACYL CHAIN REMODELING | 7 | 26 | 1.577e-13 | 1.631e-11 |
| 46 | LOCOMOTION | 20 | 1114 | 1.618e-13 | 1.637e-11 |
| 47 | EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 8 | 55 | 5.565e-13 | 5.51e-11 |
| 48 | PHOSPHATIDYLGLYCEROL METABOLIC PROCESS | 7 | 31 | 6.25e-13 | 6.059e-11 |
| 49 | CELLULAR LIPID METABOLIC PROCESS | 18 | 913 | 8.21e-13 | 7.64e-11 |
| 50 | LIPID BIOSYNTHETIC PROCESS | 15 | 539 | 8.048e-13 | 7.64e-11 |
| 51 | PHOSPHATIDYLINOSITOL ACYL CHAIN REMODELING | 6 | 16 | 9.512e-13 | 8.678e-11 |
| 52 | FC GAMMA RECEPTOR SIGNALING PATHWAY | 9 | 95 | 9.81e-13 | 8.778e-11 |
| 53 | IMMUNE SYSTEM PROCESS | 24 | 1984 | 1.209e-12 | 1.043e-10 |
| 54 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 14 | 450 | 1.21e-12 | 1.043e-10 |
| 55 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 23 | 1791 | 1.338e-12 | 1.132e-10 |
| 56 | PHOSPHATIDYLSERINE ACYL CHAIN REMODELING | 6 | 17 | 1.467e-12 | 1.177e-10 |
| 57 | PHOSPHATIDYLGLYCEROL ACYL CHAIN REMODELING | 6 | 17 | 1.467e-12 | 1.177e-10 |
| 58 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 12 | 279 | 1.451e-12 | 1.177e-10 |
| 59 | REGULATION OF TRANSPORT | 23 | 1804 | 1.556e-12 | 1.227e-10 |
| 60 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 14 | 470 | 2.175e-12 | 1.686e-10 |
| 61 | CELL MOTILITY | 17 | 835 | 2.557e-12 | 1.919e-10 |
| 62 | LOCALIZATION OF CELL | 17 | 835 | 2.557e-12 | 1.919e-10 |
| 63 | LIPID METABOLIC PROCESS | 19 | 1158 | 3.958e-12 | 2.923e-10 |
| 64 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 40 | 4.362e-12 | 3.171e-10 |
| 65 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 21 | 1518 | 4.913e-12 | 3.517e-10 |
| 66 | ERBB SIGNALING PATHWAY | 8 | 79 | 1.144e-11 | 8.064e-10 |
| 67 | POSITIVE REGULATION OF TRANSPORT | 17 | 936 | 1.563e-11 | 1.085e-09 |
| 68 | REGULATION OF LIPID KINASE ACTIVITY | 7 | 48 | 1.699e-11 | 1.162e-09 |
| 69 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 19 | 1275 | 2.12e-11 | 1.429e-09 |
| 70 | TAXIS | 13 | 464 | 3.275e-11 | 2.177e-09 |
| 71 | PLATELET ACTIVATION | 9 | 142 | 3.846e-11 | 2.521e-09 |
| 72 | REGULATION OF LIPID METABOLIC PROCESS | 11 | 282 | 4.003e-11 | 2.587e-09 |
| 73 | PHOSPHATIDYLSERINE METABOLIC PROCESS | 6 | 28 | 4.381e-11 | 2.793e-09 |
| 74 | POSITIVE REGULATION OF GENE EXPRESSION | 21 | 1733 | 6.052e-11 | 3.805e-09 |
| 75 | REGULATION OF INTRACELLULAR TRANSPORT | 14 | 621 | 8.887e-11 | 5.514e-09 |
| 76 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 7 | 61 | 9.838e-11 | 6.023e-09 |
| 77 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 13 | 514 | 1.162e-10 | 7.023e-09 |
| 78 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 15 | 771 | 1.283e-10 | 7.555e-09 |
| 79 | PHOSPHATIDIC ACID METABOLIC PROCESS | 6 | 33 | 1.277e-10 | 7.555e-09 |
| 80 | PHOSPHATIDYLCHOLINE METABOLIC PROCESS | 7 | 64 | 1.394e-10 | 8.105e-09 |
| 81 | ALDITOL PHOSPHATE METABOLIC PROCESS | 6 | 35 | 1.865e-10 | 1.071e-08 |
| 82 | REGULATION OF CELLULAR LOCALIZATION | 18 | 1277 | 2.139e-10 | 1.214e-08 |
| 83 | REGULATION OF CELL SUBSTRATE ADHESION | 9 | 173 | 2.26e-10 | 1.267e-08 |
| 84 | ERBB2 SIGNALING PATHWAY | 6 | 39 | 3.722e-10 | 2.062e-08 |
| 85 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 17 | 1152 | 3.978e-10 | 2.178e-08 |
| 86 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 5 | 18 | 4.82e-10 | 2.608e-08 |
| 87 | PHAGOCYTOSIS | 9 | 190 | 5.202e-10 | 2.782e-08 |
| 88 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 16 | 1021 | 6.38e-10 | 3.373e-08 |
| 89 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 9 | 195 | 6.549e-10 | 3.424e-08 |
| 90 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 11 | 370 | 7.189e-10 | 3.717e-08 |
| 91 | REGULATION OF CYTOPLASMIC TRANSPORT | 12 | 481 | 7.953e-10 | 4.066e-08 |
| 92 | ORGANOPHOSPHATE METABOLIC PROCESS | 15 | 885 | 8.655e-10 | 4.377e-08 |
| 93 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 18 | 1395 | 8.927e-10 | 4.467e-08 |
| 94 | ACTIVATION OF MAPK ACTIVITY | 8 | 137 | 9.906e-10 | 4.903e-08 |
| 95 | ETHANOLAMINE CONTAINING COMPOUND METABOLIC PROCESS | 7 | 85 | 1.067e-09 | 5.227e-08 |
| 96 | RESPONSE TO EXTERNAL STIMULUS | 20 | 1821 | 1.213e-09 | 5.88e-08 |
| 97 | ANGIOGENESIS | 10 | 293 | 1.254e-09 | 6.014e-08 |
| 98 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 6 | 49 | 1.567e-09 | 7.441e-08 |
| 99 | CALCIUM MEDIATED SIGNALING | 7 | 90 | 1.601e-09 | 7.451e-08 |
| 100 | REGULATION OF CELL MATRIX ADHESION | 7 | 90 | 1.601e-09 | 7.451e-08 |
| 101 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 11 | 404 | 1.809e-09 | 8.335e-08 |
| 102 | PEPTIDYL SERINE MODIFICATION | 8 | 148 | 1.831e-09 | 8.354e-08 |
| 103 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 5 | 23 | 1.876e-09 | 8.477e-08 |
| 104 | REGULATION OF PROTEIN LOCALIZATION | 15 | 950 | 2.283e-09 | 1.021e-07 |
| 105 | POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 5 | 25 | 2.952e-09 | 1.296e-07 |
| 106 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 2.952e-09 | 1.296e-07 |
| 107 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 16 | 1142 | 3.222e-09 | 1.401e-07 |
| 108 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 7 | 103 | 4.151e-09 | 1.788e-07 |
| 109 | REGULATION OF EPITHELIAL CELL MIGRATION | 8 | 166 | 4.541e-09 | 1.938e-07 |
| 110 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 6 | 59 | 4.962e-09 | 2.099e-07 |
| 111 | CELL ACTIVATION | 12 | 568 | 5.175e-09 | 2.169e-07 |
| 112 | LIPID CATABOLIC PROCESS | 9 | 247 | 5.231e-09 | 2.173e-07 |
| 113 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 10 | 352 | 7.291e-09 | 3.002e-07 |
| 114 | REGULATION OF ENDOTHELIAL CELL MIGRATION | 7 | 114 | 8.455e-09 | 3.451e-07 |
| 115 | VASCULATURE DEVELOPMENT | 11 | 469 | 8.535e-09 | 3.453e-07 |
| 116 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 10 | 360 | 9.03e-09 | 3.622e-07 |
| 117 | BLOOD VESSEL MORPHOGENESIS | 10 | 364 | 1.003e-08 | 3.989e-07 |
| 118 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 6 | 67 | 1.084e-08 | 4.273e-07 |
| 119 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 7 | 120 | 1.21e-08 | 4.73e-07 |
| 120 | IMMUNE EFFECTOR PROCESS | 11 | 486 | 1.232e-08 | 4.778e-07 |
| 121 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 12 | 1.307e-08 | 5.025e-07 |
| 122 | REGULATION OF RESPONSE TO STRESS | 17 | 1468 | 1.565e-08 | 5.968e-07 |
| 123 | REGULATION OF CELL ADHESION | 12 | 629 | 1.61e-08 | 6.089e-07 |
| 124 | REGULATION OF CELL DEATH | 17 | 1472 | 1.629e-08 | 6.115e-07 |
| 125 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 9 | 282 | 1.653e-08 | 6.154e-07 |
| 126 | POSITIVE REGULATION OF LIPID METABOLIC PROCESS | 7 | 128 | 1.895e-08 | 6.999e-07 |
| 127 | REGULATION OF CELL DIFFERENTIATION | 17 | 1492 | 1.991e-08 | 7.238e-07 |
| 128 | ENDOCYTOSIS | 11 | 509 | 1.982e-08 | 7.238e-07 |
| 129 | AMINE METABOLIC PROCESS | 7 | 131 | 2.226e-08 | 8.028e-07 |
| 130 | POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 9 | 296 | 2.511e-08 | 8.989e-07 |
| 131 | SINGLE ORGANISM BIOSYNTHETIC PROCESS | 16 | 1340 | 3.116e-08 | 1.107e-06 |
| 132 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 7 | 138 | 3.192e-08 | 1.125e-06 |
| 133 | HEMOSTASIS | 9 | 311 | 3.841e-08 | 1.344e-06 |
| 134 | RAS PROTEIN SIGNAL TRANSDUCTION | 7 | 143 | 4.082e-08 | 1.417e-06 |
| 135 | REGULATION OF ORGANELLE ORGANIZATION | 15 | 1178 | 4.11e-08 | 1.417e-06 |
| 136 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 14 | 1004 | 4.261e-08 | 1.458e-06 |
| 137 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 5 | 42 | 4.588e-08 | 1.558e-06 |
| 138 | CELLULAR RESPONSE TO INSULIN STIMULUS | 7 | 146 | 4.71e-08 | 1.577e-06 |
| 139 | T CELL RECEPTOR SIGNALING PATHWAY | 7 | 146 | 4.71e-08 | 1.577e-06 |
| 140 | RESPONSE TO NITROGEN COMPOUND | 13 | 859 | 5.604e-08 | 1.862e-06 |
| 141 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 17 | 6.229e-08 | 2.055e-06 |
| 142 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 11 | 573 | 6.629e-08 | 2.172e-06 |
| 143 | SECOND MESSENGER MEDIATED SIGNALING | 7 | 160 | 8.837e-08 | 2.876e-06 |
| 144 | REGULATION OF VESICLE MEDIATED TRANSPORT | 10 | 462 | 9.457e-08 | 3.056e-06 |
| 145 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 17 | 1672 | 1.061e-07 | 3.404e-06 |
| 146 | WOUND HEALING | 10 | 470 | 1.109e-07 | 3.536e-06 |
| 147 | REGULATION OF ADHERENS JUNCTION ORGANIZATION | 5 | 50 | 1.127e-07 | 3.567e-06 |
| 148 | LIPID PHOSPHORYLATION | 6 | 99 | 1.15e-07 | 3.616e-06 |
| 149 | REGULATION OF GLUCOSE TRANSPORT | 6 | 100 | 1.221e-07 | 3.814e-06 |
| 150 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 5 | 51 | 1.247e-07 | 3.843e-06 |
| 151 | REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 5 | 51 | 1.247e-07 | 3.843e-06 |
| 152 | AMMONIUM ION METABOLIC PROCESS | 7 | 169 | 1.285e-07 | 3.934e-06 |
| 153 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 8 | 258 | 1.401e-07 | 4.232e-06 |
| 154 | TISSUE HOMEOSTASIS | 7 | 171 | 1.393e-07 | 4.232e-06 |
| 155 | REGULATION OF CELL PROLIFERATION | 16 | 1496 | 1.438e-07 | 4.318e-06 |
| 156 | POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE | 7 | 172 | 1.449e-07 | 4.322e-06 |
| 157 | POSITIVE REGULATION OF PROTEIN IMPORT | 6 | 104 | 1.544e-07 | 4.575e-06 |
| 158 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 12 | 788 | 1.888e-07 | 5.525e-06 |
| 159 | CIRCULATORY SYSTEM DEVELOPMENT | 12 | 788 | 1.888e-07 | 5.525e-06 |
| 160 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 8 | 272 | 2.098e-07 | 6.101e-06 |
| 161 | REGULATION OF BODY FLUID LEVELS | 10 | 506 | 2.197e-07 | 6.311e-06 |
| 162 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 12 | 799 | 2.192e-07 | 6.311e-06 |
| 163 | CELLULAR RESPONSE TO PEPTIDE | 8 | 274 | 2.218e-07 | 6.333e-06 |
| 164 | POSITIVE REGULATION OF CELL PROLIFERATION | 12 | 814 | 2.676e-07 | 7.594e-06 |
| 165 | REGULATION OF GLUCOSE IMPORT | 5 | 60 | 2.855e-07 | 8.05e-06 |
| 166 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 12 | 823 | 3.011e-07 | 8.44e-06 |
| 167 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 15 | 1381 | 3.28e-07 | 9.138e-06 |
| 168 | RESPONSE TO PEPTIDE | 9 | 404 | 3.54e-07 | 9.805e-06 |
| 169 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 121 | 3.795e-07 | 1.045e-05 |
| 170 | INOSITOL LIPID MEDIATED SIGNALING | 6 | 124 | 4.386e-07 | 1.2e-05 |
| 171 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 17 | 1848 | 4.476e-07 | 1.218e-05 |
| 172 | RESPONSE TO INSULIN | 7 | 205 | 4.767e-07 | 1.29e-05 |
| 173 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 10 | 552 | 4.885e-07 | 1.306e-05 |
| 174 | REGULATION OF CELL MORPHOGENESIS | 10 | 552 | 4.885e-07 | 1.306e-05 |
| 175 | REGULATION OF PROTEIN TARGETING | 8 | 307 | 5.26e-07 | 1.399e-05 |
| 176 | REGULATION OF CELL JUNCTION ASSEMBLY | 5 | 68 | 5.372e-07 | 1.417e-05 |
| 177 | REGULATION OF CELL PROJECTION ORGANIZATION | 10 | 558 | 5.392e-07 | 1.417e-05 |
| 178 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 129 | 5.538e-07 | 1.448e-05 |
| 179 | LIPID MODIFICATION | 7 | 210 | 5.607e-07 | 1.458e-05 |
| 180 | RESPONSE TO WOUNDING | 10 | 563 | 5.849e-07 | 1.512e-05 |
| 181 | RESPONSE TO ENDOGENOUS STIMULUS | 15 | 1450 | 6.128e-07 | 1.575e-05 |
| 182 | POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 6 | 133 | 6.629e-07 | 1.695e-05 |
| 183 | POSITIVE REGULATION OF HOMEOSTATIC PROCESS | 7 | 216 | 6.777e-07 | 1.723e-05 |
| 184 | CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 4 | 30 | 7.013e-07 | 1.774e-05 |
| 185 | REGULATION OF HOMEOSTATIC PROCESS | 9 | 447 | 8.238e-07 | 2.072e-05 |
| 186 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 12 | 926 | 1.053e-06 | 2.635e-05 |
| 187 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 8 | 337 | 1.061e-06 | 2.64e-05 |
| 188 | INSULIN RECEPTOR SIGNALING PATHWAY | 5 | 80 | 1.213e-06 | 3.003e-05 |
| 189 | REGULATION OF ERK1 AND ERK2 CASCADE | 7 | 238 | 1.297e-06 | 3.194e-05 |
| 190 | ALCOHOL METABOLIC PROCESS | 8 | 348 | 1.349e-06 | 3.304e-05 |
| 191 | HOMEOSTATIC PROCESS | 14 | 1337 | 1.404e-06 | 3.421e-05 |
| 192 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 12 | 957 | 1.488e-06 | 3.606e-05 |
| 193 | POSITIVE REGULATION OF DEFENSE RESPONSE | 8 | 364 | 1.887e-06 | 4.549e-05 |
| 194 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 8 | 370 | 2.131e-06 | 5.11e-05 |
| 195 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 9 | 505 | 2.255e-06 | 5.38e-05 |
| 196 | POSITIVE REGULATION OF CELL ADHESION | 8 | 376 | 2.401e-06 | 5.7e-05 |
| 197 | REGULATION OF CELL CELL ADHESION | 8 | 380 | 2.597e-06 | 6.133e-05 |
| 198 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 8 | 381 | 2.648e-06 | 6.222e-05 |
| 199 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 5 | 95 | 2.848e-06 | 6.66e-05 |
| 200 | PEPTIDYL AMINO ACID MODIFICATION | 11 | 841 | 2.958e-06 | 6.883e-05 |
| 201 | RESPONSE TO ABIOTIC STIMULUS | 12 | 1024 | 3.01e-06 | 6.899e-05 |
| 202 | ICOSANOID METABOLIC PROCESS | 5 | 96 | 3e-06 | 6.899e-05 |
| 203 | FATTY ACID DERIVATIVE METABOLIC PROCESS | 5 | 96 | 3e-06 | 6.899e-05 |
| 204 | DEFENSE RESPONSE | 13 | 1231 | 3.36e-06 | 7.663e-05 |
| 205 | VESICLE MEDIATED TRANSPORT | 13 | 1239 | 3.608e-06 | 8.19e-05 |
| 206 | ICOSANOID BIOSYNTHETIC PROCESS | 4 | 46 | 4.063e-06 | 9.132e-05 |
| 207 | FATTY ACID DERIVATIVE BIOSYNTHETIC PROCESS | 4 | 46 | 4.063e-06 | 9.132e-05 |
| 208 | REGULATION OF PROTEIN IMPORT | 6 | 183 | 4.251e-06 | 9.51e-05 |
| 209 | ANATOMICAL STRUCTURE HOMEOSTASIS | 7 | 285 | 4.281e-06 | 9.53e-05 |
| 210 | ARACHIDONIC ACID SECRETION | 3 | 14 | 4.348e-06 | 9.588e-05 |
| 211 | ARACHIDONATE TRANSPORT | 3 | 14 | 4.348e-06 | 9.588e-05 |
| 212 | REGULATION OF RESPONSE TO WOUNDING | 8 | 413 | 4.8e-06 | 0.0001054 |
| 213 | RESPONSE TO HORMONE | 11 | 893 | 5.259e-06 | 0.0001149 |
| 214 | REGULATION OF CYTOKINE PRODUCTION | 9 | 563 | 5.464e-06 | 0.0001188 |
| 215 | UNSATURATED FATTY ACID METABOLIC PROCESS | 5 | 109 | 5.604e-06 | 0.0001207 |
| 216 | PROTEIN AUTOPHOSPHORYLATION | 6 | 192 | 5.603e-06 | 0.0001207 |
| 217 | TISSUE DEVELOPMENT | 14 | 1518 | 6.233e-06 | 0.0001337 |
| 218 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 7 | 303 | 6.395e-06 | 0.0001365 |
| 219 | REGULATION OF EARLY ENDOSOME TO LATE ENDOSOME TRANSPORT | 3 | 16 | 6.667e-06 | 0.0001416 |
| 220 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 7 | 307 | 6.967e-06 | 0.0001474 |
| 221 | IMMUNE SYSTEM DEVELOPMENT | 9 | 582 | 7.142e-06 | 0.0001504 |
| 222 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 8.082e-06 | 0.0001694 |
| 223 | NEURON PROJECTION GUIDANCE | 6 | 205 | 8.154e-06 | 0.0001694 |
| 224 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 15 | 1784 | 8.145e-06 | 0.0001694 |
| 225 | REGULATION OF DEFENSE RESPONSE | 10 | 759 | 8.457e-06 | 0.0001749 |
| 226 | CYTOKINE PRODUCTION | 5 | 120 | 8.967e-06 | 0.0001838 |
| 227 | POSITIVE REGULATION OF CHEMOTAXIS | 5 | 120 | 8.967e-06 | 0.0001838 |
| 228 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 10 | 767 | 9.27e-06 | 0.0001892 |
| 229 | ENDOTHELIAL CELL MIGRATION | 4 | 57 | 9.65e-06 | 0.0001961 |
| 230 | SINGLE ORGANISM CATABOLIC PROCESS | 11 | 957 | 1.014e-05 | 0.0002051 |
| 231 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 218 | 1.158e-05 | 0.0002332 |
| 232 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 220 | 1.219e-05 | 0.0002435 |
| 233 | CELLULAR MODIFIED AMINO ACID METABOLIC PROCESS | 6 | 220 | 1.219e-05 | 0.0002435 |
| 234 | ICOSANOID TRANSPORT | 3 | 20 | 1.348e-05 | 0.0002669 |
| 235 | FATTY ACID DERIVATIVE TRANSPORT | 3 | 20 | 1.348e-05 | 0.0002669 |
| 236 | ORGANIC HYDROXY COMPOUND METABOLIC PROCESS | 8 | 482 | 1.478e-05 | 0.0002915 |
| 237 | REGULATION OF CELL ACTIVATION | 8 | 484 | 1.523e-05 | 0.0002991 |
| 238 | POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION | 3 | 21 | 1.57e-05 | 0.0003057 |
| 239 | BONE RESORPTION | 3 | 21 | 1.57e-05 | 0.0003057 |
| 240 | REGULATION OF VASCULATURE DEVELOPMENT | 6 | 233 | 1.688e-05 | 0.0003273 |
| 241 | PLACENTA DEVELOPMENT | 5 | 138 | 1.767e-05 | 0.0003412 |
| 242 | MUSCLE CELL DIFFERENTIATION | 6 | 237 | 1.859e-05 | 0.0003574 |
| 243 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 7 | 365 | 2.136e-05 | 0.000409 |
| 244 | REGULATION OF POSITIVE CHEMOTAXIS | 3 | 24 | 2.378e-05 | 0.000448 |
| 245 | POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY | 3 | 24 | 2.378e-05 | 0.000448 |
| 246 | REGULATION OF ANOIKIS | 3 | 24 | 2.378e-05 | 0.000448 |
| 247 | POSITIVE REGULATION OF LAMELLIPODIUM ORGANIZATION | 3 | 24 | 2.378e-05 | 0.000448 |
| 248 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 5 | 152 | 2.815e-05 | 0.000526 |
| 249 | NEGATIVE REGULATION OF CELL DEATH | 10 | 872 | 2.81e-05 | 0.000526 |
| 250 | RESPONSE TO BACTERIUM | 8 | 528 | 2.842e-05 | 0.000529 |
| 251 | CELLULAR GLUCOSE HOMEOSTASIS | 4 | 75 | 2.879e-05 | 0.0005337 |
| 252 | REGULATION OF PROTEIN SECRETION | 7 | 389 | 3.209e-05 | 0.000592 |
| 253 | RESPONSE TO BIOTIC STIMULUS | 10 | 886 | 3.219e-05 | 0.000592 |
| 254 | LYMPHOCYTE COSTIMULATION | 4 | 78 | 3.361e-05 | 0.0006133 |
| 255 | REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 4 | 78 | 3.361e-05 | 0.0006133 |
| 256 | RESPONSE TO LITHIUM ION | 3 | 27 | 3.42e-05 | 0.0006215 |
| 257 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 5 | 162 | 3.82e-05 | 0.0006915 |
| 258 | CELLULAR RESPONSE TO HORMONE STIMULUS | 8 | 552 | 3.898e-05 | 0.000703 |
| 259 | REGULATION OF NEURON DIFFERENTIATION | 8 | 554 | 3.999e-05 | 0.0007185 |
| 260 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 7 | 406 | 4.211e-05 | 0.0007536 |
| 261 | REGULATION OF VACUOLAR TRANSPORT | 3 | 29 | 4.258e-05 | 0.0007591 |
| 262 | REPRODUCTIVE SYSTEM DEVELOPMENT | 7 | 408 | 4.344e-05 | 0.0007715 |
| 263 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 5 | 167 | 4.416e-05 | 0.00078 |
| 264 | CELLULAR RESPONSE TO STRESS | 13 | 1565 | 4.425e-05 | 0.00078 |
| 265 | TISSUE MIGRATION | 4 | 84 | 4.5e-05 | 0.0007902 |
| 266 | REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 6 | 278 | 4.547e-05 | 0.0007925 |
| 267 | RESPONSE TO CARBOHYDRATE | 5 | 168 | 4.544e-05 | 0.0007925 |
| 268 | EPHRIN RECEPTOR SIGNALING PATHWAY | 4 | 85 | 4.714e-05 | 0.0008185 |
| 269 | STRIATED MUSCLE CELL DIFFERENTIATION | 5 | 173 | 5.225e-05 | 0.0009004 |
| 270 | HOMEOSTASIS OF NUMBER OF CELLS WITHIN A TISSUE | 3 | 31 | 5.22e-05 | 0.0009004 |
| 271 | POSITIVE REGULATION OF LIPID KINASE ACTIVITY | 3 | 32 | 5.751e-05 | 0.0009874 |
| 272 | LEUKOCYTE DIFFERENTIATION | 6 | 292 | 5.973e-05 | 0.001022 |
| 273 | CELLULAR SENESCENCE | 3 | 33 | 6.316e-05 | 0.001065 |
| 274 | REGULATION OF CHEMOTAXIS | 5 | 180 | 6.307e-05 | 0.001065 |
| 275 | POSITIVE REGULATION OF FATTY ACID METABOLIC PROCESS | 3 | 33 | 6.316e-05 | 0.001065 |
| 276 | LEUKOTRIENE METABOLIC PROCESS | 3 | 33 | 6.316e-05 | 0.001065 |
| 277 | FATTY ACID METABOLIC PROCESS | 6 | 296 | 6.44e-05 | 0.001082 |
| 278 | NEUROGENESIS | 12 | 1402 | 7.02e-05 | 0.001175 |
| 279 | MODULATION OF SYNAPTIC TRANSMISSION | 6 | 301 | 7.065e-05 | 0.001178 |
| 280 | PEPTIDYL TYROSINE MODIFICATION | 5 | 186 | 7.367e-05 | 0.001224 |
| 281 | POSITIVE REGULATION OF CELL DEATH | 8 | 605 | 7.428e-05 | 0.00123 |
| 282 | BONE REMODELING | 3 | 35 | 7.551e-05 | 0.001246 |
| 283 | MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 96 | 7.59e-05 | 0.001248 |
| 284 | CELL DEVELOPMENT | 12 | 1426 | 8.269e-05 | 0.001355 |
| 285 | MYELOID LEUKOCYTE MIGRATION | 4 | 99 | 8.556e-05 | 0.001387 |
| 286 | INFLAMMATORY RESPONSE | 7 | 454 | 8.507e-05 | 0.001387 |
| 287 | POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 4 | 99 | 8.556e-05 | 0.001387 |
| 288 | REGULATION OF LAMELLIPODIUM ORGANIZATION | 3 | 37 | 8.935e-05 | 0.001444 |
| 289 | CELL DEATH | 10 | 1001 | 8.99e-05 | 0.001447 |
| 290 | SINGLE ORGANISM CELL ADHESION | 7 | 459 | 9.109e-05 | 0.001461 |
| 291 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 10 | 1008 | 9.526e-05 | 0.001523 |
| 292 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 3 | 39 | 0.0001047 | 0.001658 |
| 293 | PEPTIDYL TYROSINE AUTOPHOSPHORYLATION | 3 | 39 | 0.0001047 | 0.001658 |
| 294 | POSITIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 3 | 39 | 0.0001047 | 0.001658 |
| 295 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 4 | 106 | 0.0001116 | 0.00176 |
| 296 | POSITIVE REGULATION OF CELL MATRIX ADHESION | 3 | 40 | 0.0001131 | 0.001771 |
| 297 | RESPONSE TO GROWTH FACTOR | 7 | 475 | 0.0001127 | 0.001771 |
| 298 | ACTIVATION OF INNATE IMMUNE RESPONSE | 5 | 204 | 0.0001138 | 0.001778 |
| 299 | ORGAN MORPHOGENESIS | 9 | 841 | 0.0001273 | 0.001981 |
| 300 | POSITIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 3 | 42 | 0.0001309 | 0.002024 |
| 301 | LONG CHAIN FATTY ACID TRANSPORT | 3 | 42 | 0.0001309 | 0.002024 |
| 302 | POSITIVE REGULATION OF PROTEIN SECRETION | 5 | 211 | 0.0001333 | 0.002054 |
| 303 | REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 3 | 43 | 0.0001405 | 0.002158 |
| 304 | SMALL MOLECULE METABOLIC PROCESS | 13 | 1767 | 0.0001536 | 0.00235 |
| 305 | REGULATION OF MITOCHONDRION ORGANIZATION | 5 | 218 | 0.0001553 | 0.002369 |
| 306 | LUNG MORPHOGENESIS | 3 | 45 | 0.000161 | 0.002449 |
| 307 | LEUKOCYTE CHEMOTAXIS | 4 | 117 | 0.0001634 | 0.002476 |
| 308 | CHEMICAL HOMEOSTASIS | 9 | 874 | 0.0001702 | 0.002571 |
| 309 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 7 | 513 | 0.0001813 | 0.00273 |
| 310 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 5 | 228 | 0.0001914 | 0.002872 |
| 311 | REGULATION OF SECRETION | 8 | 699 | 0.0002012 | 0.00301 |
| 312 | REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 5 | 232 | 0.0002075 | 0.003094 |
| 313 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 6 | 368 | 0.0002116 | 0.003146 |
| 314 | MUSCLE CELL DEVELOPMENT | 4 | 128 | 0.0002307 | 0.003419 |
| 315 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 4 | 131 | 0.0002521 | 0.003724 |
| 316 | NEURON PROJECTION DEVELOPMENT | 7 | 545 | 0.0002623 | 0.003863 |
| 317 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 5 | 246 | 0.000272 | 0.003993 |
| 318 | B CELL RECEPTOR SIGNALING PATHWAY | 3 | 54 | 0.0002774 | 0.004058 |
| 319 | POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 2 | 11 | 0.0002933 | 0.004238 |
| 320 | CHEMICAL HOMEOSTASIS WITHIN A TISSUE | 2 | 11 | 0.0002933 | 0.004238 |
| 321 | REGULATION OF FEVER GENERATION | 2 | 11 | 0.0002933 | 0.004238 |
| 322 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 2 | 11 | 0.0002933 | 0.004238 |
| 323 | CELLULAR RESPONSE TO RADIATION | 4 | 137 | 0.0002991 | 0.004308 |
| 324 | EPITHELIUM DEVELOPMENT | 9 | 945 | 0.0003045 | 0.004373 |
| 325 | GLAND DEVELOPMENT | 6 | 395 | 0.0003094 | 0.004417 |
| 326 | FATTY ACID TRANSPORT | 3 | 56 | 0.000309 | 0.004417 |
| 327 | NON CANONICAL WNT SIGNALING PATHWAY | 4 | 140 | 0.0003248 | 0.004591 |
| 328 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 8 | 750 | 0.0003239 | 0.004591 |
| 329 | POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 3 | 57 | 0.0003256 | 0.004591 |
| 330 | REGULATION OF SYNAPTIC PLASTICITY | 4 | 140 | 0.0003248 | 0.004591 |
| 331 | NEURON PROJECTION MORPHOGENESIS | 6 | 402 | 0.0003399 | 0.004777 |
| 332 | UNSATURATED FATTY ACID BIOSYNTHETIC PROCESS | 3 | 58 | 0.0003428 | 0.004804 |
| 333 | CELLULAR CHEMICAL HOMEOSTASIS | 7 | 570 | 0.0003442 | 0.004809 |
| 334 | REGULATION OF GOLGI ORGANIZATION | 2 | 12 | 0.0003514 | 0.004838 |
| 335 | X3 UTR MEDIATED MRNA STABILIZATION | 2 | 12 | 0.0003514 | 0.004838 |
| 336 | REGULATION OF BROWN FAT CELL DIFFERENTIATION | 2 | 12 | 0.0003514 | 0.004838 |
| 337 | CEREBRAL CORTEX GABAERGIC INTERNEURON DIFFERENTIATION | 2 | 12 | 0.0003514 | 0.004838 |
| 338 | TRACHEA MORPHOGENESIS | 2 | 12 | 0.0003514 | 0.004838 |
| 339 | VASCULOGENESIS | 3 | 59 | 0.0003605 | 0.004949 |
| 340 | ESTABLISHMENT OF PROTEIN LOCALIZATION | 11 | 1423 | 0.0003647 | 0.004991 |
| 341 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 6 | 408 | 0.0003677 | 0.005018 |
| 342 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 5 | 263 | 0.0003698 | 0.005031 |
| 343 | MATERNAL PROCESS INVOLVED IN FEMALE PREGNANCY | 3 | 60 | 0.0003789 | 0.00514 |
| 344 | RESPONSE TO OSMOTIC STRESS | 3 | 63 | 0.0004375 | 0.005918 |
| 345 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 4 | 154 | 0.0004661 | 0.006268 |
| 346 | AMEBOIDAL TYPE CELL MIGRATION | 4 | 154 | 0.0004661 | 0.006268 |
| 347 | REGULATION OF RESPIRATORY BURST | 2 | 14 | 0.0004831 | 0.006368 |
| 348 | VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 2 | 14 | 0.0004831 | 0.006368 |
| 349 | CARDIOLIPIN METABOLIC PROCESS | 2 | 14 | 0.0004831 | 0.006368 |
| 350 | REGULATION OF PROTEIN KINASE C SIGNALING | 2 | 14 | 0.0004831 | 0.006368 |
| 351 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 7 | 602 | 0.0004777 | 0.006368 |
| 352 | POSITIVE REGULATION OF SPROUTING ANGIOGENESIS | 2 | 14 | 0.0004831 | 0.006368 |
| 353 | REGULATION OF CELL PROJECTION ASSEMBLY | 4 | 155 | 0.0004776 | 0.006368 |
| 354 | ACID SECRETION | 3 | 66 | 0.0005017 | 0.006539 |
| 355 | CELLULAR RESPONSE TO UV | 3 | 66 | 0.0005017 | 0.006539 |
| 356 | MUSCLE STRUCTURE DEVELOPMENT | 6 | 432 | 0.0004978 | 0.006539 |
| 357 | POSITIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 3 | 66 | 0.0005017 | 0.006539 |
| 358 | CELL AGING | 3 | 67 | 0.0005244 | 0.006815 |
| 359 | CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 2 | 15 | 0.0005566 | 0.007095 |
| 360 | REGULATION OF HEAT GENERATION | 2 | 15 | 0.0005566 | 0.007095 |
| 361 | NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS | 2 | 15 | 0.0005566 | 0.007095 |
| 362 | GABAERGIC NEURON DIFFERENTIATION | 2 | 15 | 0.0005566 | 0.007095 |
| 363 | REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 2 | 15 | 0.0005566 | 0.007095 |
| 364 | REGULATION OF DNA REPLICATION | 4 | 161 | 0.0005511 | 0.007095 |
| 365 | POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 3 | 68 | 0.0005476 | 0.007095 |
| 366 | CELL CHEMOTAXIS | 4 | 162 | 0.0005641 | 0.007151 |
| 367 | POSITIVE REGULATION OF RESPONSE TO WOUNDING | 4 | 162 | 0.0005641 | 0.007151 |
| 368 | REGULATION OF DEVELOPMENTAL GROWTH | 5 | 289 | 0.0005682 | 0.007184 |
| 369 | POSITIVE REGULATION OF AXONOGENESIS | 3 | 69 | 0.0005716 | 0.007208 |
| 370 | VASCULAR PROCESS IN CIRCULATORY SYSTEM | 4 | 163 | 0.0005773 | 0.007259 |
| 371 | CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 3 | 70 | 0.0005962 | 0.007478 |
| 372 | ACTIN FILAMENT BASED PROCESS | 6 | 450 | 0.0006169 | 0.007717 |
| 373 | POSITIVE REGULATION OF LAMELLIPODIUM ASSEMBLY | 2 | 16 | 0.0006352 | 0.007881 |
| 374 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 4 | 167 | 0.0006323 | 0.007881 |
| 375 | POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 2 | 16 | 0.0006352 | 0.007881 |
| 376 | REGULATION OF AXONOGENESIS | 4 | 168 | 0.0006466 | 0.008001 |
| 377 | REGULATION OF CELL DEVELOPMENT | 8 | 836 | 0.000666 | 0.00822 |
| 378 | GLUCOSE HOMEOSTASIS | 4 | 170 | 0.0006759 | 0.008276 |
| 379 | REGULATION OF ORGAN GROWTH | 3 | 73 | 0.0006741 | 0.008276 |
| 380 | CARBOHYDRATE HOMEOSTASIS | 4 | 170 | 0.0006759 | 0.008276 |
| 381 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 4 | 171 | 0.0006909 | 0.008438 |
| 382 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 3 | 74 | 0.0007014 | 0.008544 |
| 383 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 2 | 17 | 0.0007188 | 0.008642 |
| 384 | REGULATION OF CHROMATIN BINDING | 2 | 17 | 0.0007188 | 0.008642 |
| 385 | POSITIVE REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 2 | 17 | 0.0007188 | 0.008642 |
| 386 | REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 2 | 17 | 0.0007188 | 0.008642 |
| 387 | REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 2 | 17 | 0.0007188 | 0.008642 |
| 388 | GRANULOCYTE MIGRATION | 3 | 75 | 0.0007294 | 0.008748 |
| 389 | ACTIN FILAMENT ORGANIZATION | 4 | 174 | 0.0007373 | 0.00882 |
| 390 | HOMEOSTASIS OF NUMBER OF CELLS | 4 | 175 | 0.0007533 | 0.008987 |
| 391 | RESPONSE TO CORTICOSTEROID | 4 | 176 | 0.0007695 | 0.009157 |
| 392 | POSITIVE REGULATION OF CELL ACTIVATION | 5 | 311 | 0.000791 | 0.009389 |
| 393 | REGULATION OF MITOCHONDRIAL DEPOLARIZATION | 2 | 18 | 0.0008074 | 0.009511 |
| 394 | REGULATION OF CELL MATURATION | 2 | 18 | 0.0008074 | 0.009511 |
| 395 | OVULATION | 2 | 18 | 0.0008074 | 0.009511 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | PHOSPHOLIPASE A2 ACTIVITY | 8 | 31 | 3.759e-15 | 3.492e-12 |
| 2 | KINASE ACTIVITY | 19 | 842 | 1.363e-14 | 6.333e-12 |
| 3 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 19 | 992 | 2.574e-13 | 7.971e-11 |
| 4 | PHOSPHOLIPASE ACTIVITY | 9 | 94 | 8.896e-13 | 2.066e-10 |
| 5 | LIPASE ACTIVITY | 9 | 117 | 6.64e-12 | 1.234e-09 |
| 6 | RIBONUCLEOTIDE BINDING | 21 | 1860 | 2.27e-10 | 3.515e-08 |
| 7 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 70 | 2.661e-10 | 3.532e-08 |
| 8 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 6 | 43 | 6.905e-10 | 8.019e-08 |
| 9 | CARBOXYLIC ESTER HYDROLASE ACTIVITY | 8 | 135 | 8.809e-10 | 9.093e-08 |
| 10 | PROTEIN KINASE ACTIVITY | 13 | 640 | 1.69e-09 | 1.57e-07 |
| 11 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 6 | 51 | 2.011e-09 | 1.699e-07 |
| 12 | HYDROLASE ACTIVITY ACTING ON ESTER BONDS | 13 | 739 | 9.492e-09 | 7.349e-07 |
| 13 | KINASE BINDING | 12 | 606 | 1.065e-08 | 7.366e-07 |
| 14 | KINASE REGULATOR ACTIVITY | 8 | 186 | 1.11e-08 | 7.366e-07 |
| 15 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 10 | 445 | 6.666e-08 | 4.129e-06 |
| 16 | ENZYME BINDING | 17 | 1737 | 1.842e-07 | 1.07e-05 |
| 17 | ADENYL NUCLEOTIDE BINDING | 15 | 1514 | 1.061e-06 | 5.798e-05 |
| 18 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 1.981e-06 | 0.0001022 |
| 19 | CALCIUM DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 12 | 2.636e-06 | 0.0001225 |
| 20 | MAP KINASE KINASE ACTIVITY | 3 | 12 | 2.636e-06 | 0.0001225 |
| 21 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 6 | 172 | 2.972e-06 | 0.0001315 |
| 22 | CALCIUM ION BINDING | 10 | 697 | 3.992e-06 | 0.0001686 |
| 23 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 3 | 16 | 6.667e-06 | 0.0002693 |
| 24 | PROTEIN TYROSINE KINASE BINDING | 4 | 54 | 7.766e-06 | 0.0003006 |
| 25 | MOLECULAR FUNCTION REGULATOR | 12 | 1353 | 4.97e-05 | 0.001847 |
| 26 | PROTEIN TYROSINE KINASE ACTIVITY | 5 | 176 | 5.669e-05 | 0.002026 |
| 27 | CALMODULIN BINDING | 5 | 179 | 6.143e-05 | 0.002114 |
| 28 | RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY | 4 | 92 | 6.428e-05 | 0.002133 |
| 29 | PROTEIN SERINE THREONINE TYROSINE KINASE ACTIVITY | 3 | 39 | 0.0001047 | 0.003356 |
| 30 | PROTEIN KINASE C BINDING | 3 | 50 | 0.0002206 | 0.006832 |
| 31 | GTPASE ACTIVITY | 5 | 246 | 0.000272 | 0.008152 |
| 32 | GUANYL NUCLEOTIDE BINDING | 6 | 390 | 0.0002891 | 0.008392 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 1.878e-14 | 1.097e-11 |
| 2 | EXTRINSIC COMPONENT OF MEMBRANE | 11 | 252 | 1.193e-11 | 3.482e-09 |
| 3 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 7 | 237 | 1.262e-06 | 0.0002056 |
| 4 | CELL LEADING EDGE | 8 | 350 | 1.408e-06 | 0.0002056 |
| 5 | LAMELLIPODIUM | 6 | 172 | 2.972e-06 | 0.0003471 |
| 6 | PERINUCLEAR REGION OF CYTOPLASM | 9 | 642 | 1.565e-05 | 0.001523 |
| 7 | ACTIN FILAMENT | 4 | 70 | 2.191e-05 | 0.001828 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | hsa04370_VEGF_signaling_pathway | 47 | 76 | 1.599e-122 | 2.879e-120 | |
| 2 | hsa04664_Fc_epsilon_RI_signaling_pathway | 31 | 79 | 4.974e-66 | 4.477e-64 | |
| 3 | hsa04662_B_cell_receptor_signaling_pathway | 26 | 75 | 7.378e-53 | 4.427e-51 | |
| 4 | hsa04014_Ras_signaling_pathway | 31 | 236 | 2.824e-49 | 1.271e-47 | |
| 5 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 27 | 136 | 1.688e-47 | 6.077e-46 | |
| 6 | hsa04660_T_cell_receptor_signaling_pathway | 25 | 108 | 1.38e-45 | 4.139e-44 | |
| 7 | hsa04010_MAPK_signaling_pathway | 29 | 268 | 3.811e-43 | 9.801e-42 | |
| 8 | hsa04012_ErbB_signaling_pathway | 20 | 87 | 4.982e-36 | 1.121e-34 | |
| 9 | hsa04722_Neurotrophin_signaling_pathway | 20 | 127 | 2.011e-32 | 4.022e-31 | |
| 10 | hsa04912_GnRH_signaling_pathway | 19 | 101 | 2.384e-32 | 4.292e-31 | |
| 11 | hsa04510_Focal_adhesion | 21 | 200 | 3.418e-30 | 5.594e-29 | |
| 12 | hsa04730_Long.term_depression | 16 | 70 | 1.106e-28 | 1.66e-27 | |
| 13 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 17 | 95 | 1.719e-28 | 2.38e-27 | |
| 14 | hsa04380_Osteoclast_differentiation | 17 | 128 | 3.933e-26 | 5.057e-25 | |
| 15 | hsa04062_Chemokine_signaling_pathway | 18 | 189 | 5.693e-25 | 6.832e-24 | |
| 16 | hsa04670_Leukocyte_transendothelial_migration | 15 | 117 | 8.166e-23 | 9.187e-22 | |
| 17 | hsa04360_Axon_guidance | 15 | 130 | 4.287e-22 | 4.539e-21 | |
| 18 | hsa04620_Toll.like_receptor_signaling_pathway | 14 | 102 | 9.478e-22 | 9.478e-21 | |
| 19 | hsa04910_Insulin_signaling_pathway | 15 | 138 | 1.091e-21 | 1.034e-20 | |
| 20 | hsa04151_PI3K_AKT_signaling_pathway | 19 | 351 | 1.201e-21 | 1.081e-20 | |
| 21 | hsa04914_Progesterone.mediated_oocyte_maturation | 13 | 87 | 9.771e-21 | 8.375e-20 | |
| 22 | hsa04810_Regulation_of_actin_cytoskeleton | 16 | 214 | 1.879e-20 | 1.538e-19 | |
| 23 | hsa00592_alpha.Linolenic_acid_metabolism | 9 | 20 | 1.595e-19 | 1.248e-18 | |
| 24 | hsa04270_Vascular_smooth_muscle_contraction | 13 | 116 | 5.018e-19 | 3.763e-18 | |
| 25 | hsa04210_Apoptosis | 12 | 89 | 1.285e-18 | 9.249e-18 | |
| 26 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 10 | 42 | 2.564e-18 | 1.775e-17 | |
| 27 | hsa04973_Carbohydrate_digestion_and_absorption | 10 | 44 | 4.309e-18 | 2.873e-17 | |
| 28 | hsa04972_Pancreatic_secretion | 12 | 101 | 6.327e-18 | 4.067e-17 | |
| 29 | hsa00591_Linoleic_acid_metabolism | 9 | 30 | 1.335e-17 | 8.288e-17 | |
| 30 | hsa04310_Wnt_signaling_pathway | 13 | 151 | 1.728e-17 | 1.037e-16 | |
| 31 | hsa04150_mTOR_signaling_pathway | 10 | 52 | 2.711e-17 | 1.574e-16 | |
| 32 | hsa00565_Ether_lipid_metabolism | 9 | 36 | 8.697e-17 | 4.892e-16 | |
| 33 | hsa00590_Arachidonic_acid_metabolism | 10 | 59 | 1.064e-16 | 5.803e-16 | |
| 34 | hsa04720_Long.term_potentiation | 10 | 70 | 6.594e-16 | 3.491e-15 | |
| 35 | hsa04975_Fat_digestion_and_absorption | 9 | 46 | 1e-15 | 5.145e-15 | |
| 36 | hsa04070_Phosphatidylinositol_signaling_system | 10 | 78 | 2.064e-15 | 1.032e-14 | |
| 37 | hsa00564_Glycerophospholipid_metabolism | 9 | 80 | 1.987e-13 | 9.665e-13 | |
| 38 | hsa04540_Gap_junction | 8 | 90 | 3.334e-11 | 1.579e-10 | |
| 39 | hsa04630_Jak.STAT_signaling_pathway | 9 | 155 | 8.459e-11 | 3.904e-10 | |
| 40 | hsa04530_Tight_junction | 8 | 133 | 7.82e-10 | 3.519e-09 | |
| 41 | hsa04916_Melanogenesis | 7 | 101 | 3.616e-09 | 1.587e-08 | |
| 42 | hsa04020_Calcium_signaling_pathway | 6 | 177 | 3.507e-06 | 1.503e-05 | |
| 43 | hsa00562_Inositol_phosphate_metabolism | 4 | 57 | 9.65e-06 | 4.04e-05 | |
| 44 | hsa04520_Adherens_junction | 4 | 73 | 2.587e-05 | 0.0001058 | |
| 45 | hsa04114_Oocyte_meiosis | 4 | 114 | 0.0001478 | 0.0005913 | |
| 46 | hsa04320_Dorso.ventral_axis_formation | 2 | 25 | 0.001567 | 0.00613 | |
| 47 | hsa04621_NOD.like_receptor_signaling_pathway | 2 | 59 | 0.008493 | 0.03253 | |
| 48 | hsa04920_Adipocytokine_signaling_pathway | 2 | 68 | 0.01116 | 0.04184 | |
| 49 | hsa04144_Endocytosis | 3 | 203 | 0.01204 | 0.04362 | |
| 50 | hsa04622_RIG.I.like_receptor_signaling_pathway | 2 | 71 | 0.01212 | 0.04362 | |
| 51 | hsa04971_Gastric_acid_secretion | 2 | 74 | 0.01311 | 0.04628 | |
| 52 | hsa04970_Salivary_secretion | 2 | 89 | 0.01859 | 0.06435 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HCG11 |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-502-3p;hsa-miR-93-5p | 10 | AKT3 | Sponge network | -0.781 | 0 | -0.659 | 0.00047 | 0.574 |
| 2 | DHRS4-AS1 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-582-5p;hsa-miR-589-3p | 10 | PIK3R1 | Sponge network | -0.646 | 0.01829 | -0.892 | 0 | 0.557 |
| 3 | LINC00261 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-188-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-330-3p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -1.194 | 0 | -0.892 | 0 | 0.513 |
| 4 | RP11-12A2.3 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -4.779 | 0 | -0.892 | 0 | 0.489 |
| 5 | LINC01018 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-338-5p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -3.231 | 0 | -0.892 | 0 | 0.472 |
| 6 | LDLRAD4-AS1 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -3.366 | 0 | -0.892 | 0 | 0.45 |
| 7 | RP11-119D9.1 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-188-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -2.765 | 0 | -0.892 | 0 | 0.418 |
| 8 | RP11-290F5.1 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p | 11 | PIK3R1 | Sponge network | -1.679 | 5.0E-5 | -0.892 | 0 | 0.402 |
| 9 | LINC00238 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p | 12 | PIK3R1 | Sponge network | -4.997 | 0 | -0.892 | 0 | 0.369 |
| 10 | AC004862.6 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -2.202 | 0.00081 | -0.892 | 0 | 0.357 |
| 11 | RP11-407B7.1 | hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-338-5p;hsa-miR-629-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -0.818 | 0.00584 | -0.892 | 0 | 0.324 |
| 12 | RP11-166D19.1 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-324-3p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -0.244 | 0.28835 | -0.892 | 0 | 0.32 |
| 13 | TOB1-AS1 | hsa-miR-142-5p;hsa-miR-146a-5p;hsa-miR-150-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-218-5p;hsa-miR-2355-3p;hsa-miR-330-3p;hsa-miR-450b-5p | 10 | PRKCA | Sponge network | 0.811 | 0 | 0.663 | 0 | 0.308 |
| 14 | CASC2 |
hsa-miR-148b-3p;hsa-miR-17-3p;hsa-miR-192-3p;hsa-miR-193a-3p;hsa-miR-194-3p;hsa-miR-194-5p;hsa-miR-21-5p;hsa-miR-362-5p;hsa-miR-548j-5p;hsa-miR-885-5p | 10 | NFAT5 | Sponge network | -0.596 | 0.00187 | -0.326 | 0.00164 | 0.281 |
| 15 | RP11-7F17.3 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p | 11 | PIK3R1 | Sponge network | -0.873 | 0.00204 | -0.892 | 0 | 0.271 |
| 16 | SMIM2-AS1 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p | 12 | PIK3R1 | Sponge network | -0.66 | 0.00587 | -0.892 | 0 | 0.27 |